- $1.10bn
- $1.17bn
- $256.18m
Brief: Paragon 28 Announces Preliminary Unaudited Revenue For Fourth Quarter And Full-Year 2022
Brief: Paragon 28 Inc - On November 28, 2022, The Company Entered Into A Settlement Agreement With Stryker Corp
NYSE ORDER IMBALANCE 50777.0 SHARES ON BUY SIDE
Paragon 28 rises on higher 2022 sales forecast
Paragon 28 Inc reports results for the quarter ended in September - Earnings Summary
Brief: Paragon 28 Reports Third Quarter 2022 Financial Results, Increases 2022 Net Revenue Guidance
Brief: Paragon 28 Inc Files For Mixed Shelf Of Up To $100 Mln – SEC Filing
NYSE ORDER IMBALANCE 364832.0 SHARES ON SELL SIDE
Brief: Paragon 28 Inc - Net Revenue $42.5 Million For Q2 Of 2022
NYSE ORDER IMBALANCE 415700.0 SHARES ON SELL SIDE
NYSE ORDER IMBALANCE 60391.0 SHARES ON BUY SIDE
NYSE ORDER IMBALANCE 57306.0 SHARES ON BUY SIDE
NYSE ORDER IMBALANCE 70245.0 SHARES ON BUY SIDE
NYSE ORDER IMBALANCE 66032.0 SHARES ON SELL SIDE
Paragon 28 Inc reports results for the quarter ended in March - Earnings Summary
Brief: Paragon 28 Provides 2022 Net Revenue Guidance
Brief: Paragon 28 Announces Acquisition Of Disior
Brief: Paragon 28 Announces Preliminary Unaudited Revenue For Fourth Quarter And Full-Year 2021
Brief: Paragon 28, Inc. R3ACT™ Stabilization System Cleared by FDA